Launching the First Non-Invasive Point of Care Diagnostic Test for Traumatic Brain Injury

Projektinformationen

Medicortex

ID Finanzhilfevereinbarung: 835546

DOI

10.3030/835546

Projekt abgeschlossen

EK-Unterschriftsdatum 19 November 2018

Startdatum 1 November 2018

Enddatum 28 Februar 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

MEDICORTEX FINLAND OY
Finland

Periodic Reporting for period 1 - Medicortex (Launching the First Non-Invasive Point of Care Diagnostic Test for Traumatic Brain Injury)

Berichtszeitraum: 2018-11-01 bis 2019-02-28

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Medicortex Finland Oy is a Finnish biotechnology company developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury (mild TBI). The kit is based on novel biomarkers that the company has discovered in urine and saliva following a brain injury. Generally, TBI is the leading cause of central nervous system impairment. Mild cases and concussions represent more than 90% of traumatic brain injuries but are the most difficult to accurately diagnose. Standard TBI diagnostic tools are based on CT scans, MRI scans or neurological examination which are not sufficient to diagnose mild cases, putting the patient at risks of long-term consequences of untreated TBI such as headache, dizziness, irritability, anxiety and depression and premature development of chronic neurodegenerative conditions such as Alzheimer’s or Parkinson’s diseases. TBI has become a silent epidemic. In Europe the incidence rate is 235 per 100,000 population and the global incidence is estimated to be more than 50 million cases each year. The overall objective of this feasibility study was to explore the strategies and to create a roadmap business plan for the commercialization of the ProbTBITM diagnostic kit for rapid brain injury detection.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The feasibility study comprised of setting up and engaging suppliers for further development and production of the ProbTBITM diagnostic kit as well as documenting the certification roadmap required for different user segments and regions. With help of engaged suppliers and consultants, we built the go-to-market strategy and simulated the pricing models for various sales schemes. The IP-plan to was updated to give us wider coverage and ensure the maximum freedom to operate.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

We engaged the suppliers and first distributors for the development and commercialization of the first-generation ProbTBITM to facilitate smooth launch of the product in a reasonable time. Upon documenting the certification pathways, the product development and validation studies will be carried out according to the required quality standards. Based on the market analysis and pricing models we have realistic expectations of the revenues, and we recognized new opportunities in the IP-strategy, too. As a conclusion of action, we will continue the project to further develop and commercialize the ProbTBITM diagnostic kit to give healthcare personnel and people a tool for rapid and cost-effective detection of brain injury.

Medicortex Logo